Rituximab With or Without Bevacizumab for the Treatment of Patients With Relapsed Follicular Lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rituximab With or Without Bevacizumab for the Treatment of Patients With Relapsed Follicular Lymphoma

Published:2014-08 Issue:4 Volume:14 Page:277-283
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Hainsworth John D.,Greco F. Anthony,Raefsky Eric L.,Thompson Dana S.,Lunin Scott,Reeves James,White Lynn,Quinn Raven,DeBusk Laura M.,Flinn Ian W.

Funder

Genentech, Inc

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference18 articles.

1. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network;Hainsworth;J Clin Oncol,2005

2. Results of Eastern Cooperative Oncology Group protocol E4402 (RESORT): a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma;Kahl;Blood,2011

3. Angiogenic growth factors and endostatin in non-Hodgkin lymphoma;Bertolini;Br J Haematol,1999

4. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin lymphoma;Niitsu;Eur J Haematol,2002

5. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients;Salven;Blood,2000

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling promising phytocompounds from Moringa oleifera as dual inhibitors of EGFR(T790M/C797S) and VEGFR-2 in non-small cell lung cancer through in silico screening, ADMET, dynamics simulation, and DFT analysis;Journal of Genetic Engineering and Biotechnology;2024-09

2. CD38/NAD+ glycohydrolase and associated antigens in chronic lymphocytic leukaemia: From interconnected signalling pathways to therapeutic strategies;Biochimie;2024-07

3. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01

4. Cost–effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma;Journal of Comparative Effectiveness Research;2023-12

5. Increased plasma endostatin and GDF15 in indolent non-Hodgkin lymphoma;Upsala Journal of Medical Sciences;2023-05-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3